Aimmune Therapeutics, Inc., announced that the European Commission (EC) has approved PALFORZIA for peanut allergy vaccine market

 

The growing prevalence of peanut allergy around the globe is driving the growth of the peanut allergy vaccine market. According to Food Allergy Research & Education, more than 170 foods have been reported to cause allergic reactions. Eight major food allergens – milk, egg, peanut, tree nuts, wheat, soy, fish, and crustacean shellfish – are responsible for most of the serious food allergy reactions in the United States. The incidences of peanut allergy are more prevalent in countries such as the U.K., Australia, and the U.S. According to the American Academy of Allergy Asthma & Immunology, 30.4% of children with food allergies suffered from multiple allergy attacks. Peanut allergy is such an epidemic condition in the U.S. that the federal Food Allergen Labeling and Consumer Protection Act (FALCPA) mandated that all packaged food sold in the U.S. that includes peanuts as an ingredient have to prominently display the word 'Peanut' on the label.

In February 2019, Aravax, an Australia-based biotechnology company, presented positive Phase I data for a clinical trial, evaluating the safety and tolerability of a novel vaccine ‘PVX108’ at the 2019 American Academy of Allergy, Asthma & Immunology (AAAAI). This is an intradermal peanut allergy immunotherapy vaccine.

In January 2020, The U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts

In December 2020, Aimmune Therapeutics, Inc., a Nestlé Health Science Company announced that the European Commission (EC) has approved PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy

North America is expected to hold a dominant position in the global peanut allergy vaccine market and this is attributed to the growing FDA approval for the launch of peanut allergy vaccines. For instance, in March 2019, Aimmue Therapeutics, Inc., a biopharmaceutical company, received Biologics License Application (BLA) for AR101 from the U.S. Food and Drug Administration (FDA) for review. AR101 is indicated for peanut allergy.

Peanut Allergy Vaccine is being considered as one of the best ways to protect infants against peanut allergy, as well as other types of allergies. This vaccine has been designed especially for the prevention of peanut allergy and is currently being tested on individuals. Recent studies have shown that individuals who have had prior incidents of anaphylactic shock with an allergen may be protected by this vaccine. Preliminary studies show promising results and indicate that this vaccine could very well become a major tool in the battle against allergies.